Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGFA). VEGF-A stimulates angiogenesis in a variety of diseases, including cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Sample Type:Serum and plasma
Intended Use:The Bevacizumab PK ELISA kit is designed to measure Bevacizumab in serum or plasma with high specificity and sensitivity. This sandwich ELISA design employs a Bevacizumab specific monoclonal antibody for capture and a specific monoclonal antibody for detection.
Sensitivity:<2ng/ml
Specificity:hIgG1, rituximab, and infliximab prepared at 250ng/mL were assayed and exhibited no crossreactivity or interference.
Recovery:250ng/mL of Bevacizumab was spiked in 10 lots of human serum. Recovery ranges are from 91-117% with an average recovery of 106%.
Test Principle:This assay employs the sandwich enzyme immunoassay technique. Anti- Bevacizumab is coated onto a 96 well microplate. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Bevacizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Bevacizumab present in test samples.
Storage and Stability:Store kit components at -20°C unless specified otherwise. Unopened kit is stable for 6 months after receipt. For maximum recovery of product, centrifuge small tubes on pulse setting prior to opening.
